Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Rating Reaffirmed by Piper SandlerZolmax • about 1 month ago
Day One Biopharmaceuticals (NASDAQ:DAWN Get Free Report)s stock had its overweight rating reiterated by equities research analysts at Piper Sandler in a research report...
Share to Feed
Day One Biopharmaceuticals (NASDAQ:DAWN Get Free Report)s stock had its overweight rating reaffirmed by equities research analysts at Piper Sandler in a research note...
Investors eyeing a purchase of Day One Biopharmaceuticals Inc (DAWN) stock, but cautious about paying the going market price of 15.12/share, might benefit from considering selling puts among the...
Alps Advisors Inc. raised its stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN Free Report) by 2.5% in the 3rd quarter, according to the company in its most recent filing...
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN Get Free Report) shares gapped down prior to trading on Wednesday . The stock had previously closed at $16.68, but opened at $16.34. Day One...
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN Free Report) Equities researchers at Capital One Financial issued their FY2028 earnings per share (EPS) estimates for shares of Day One...
Day One Biopharmaceuticals reports Q4 results...
PDUFA target action date for tovorafenib NDA in relapsed or progressive pLGG remains set for April 30, 2024 Phase 2 FIREFLY-1 tovorafenib registrational data published in Nature Medicine Ended 2023...
Barclays PLC decreased its position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN Free Report) by 8.7% in the third quarter, according to its most recent 13F filing with the Securities and...
Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects...